{"id":482,"company":{"country":"IL","currency":"USD","exchange":"TEL AVIV STOCK EXCHANGE","ipo":"1951-01-01","marketCap":43299.3,"name":"Teva Pharmaceutical Industries Ltd","phone":"97239267267.0","outstanding":1120.87,"symbol":"TEVA","website":"https://www.tevapharm.com/","industry":"Pharmaceuticals"},"price":9.02625,"year":2023,"month":11,"day":7,"weekday":"Tuesday","title":"Recent Developments Impacting Teva Pharmaceutical Industries Ltd","date":"2023-11-07","url":"/posts/2023/11/07/TEVA","content":[{"section":"1. FDA Approval","text":"Teva received approval from the U.S. Food and Drug Administration (FDA) for its generic version of a popular drug, which is expected to boost sales and market share in the coming months."},{"section":"2. Legal Settlement","text":"Teva reached a settlement in a lawsuit related to alleged price-fixing in the generic drug industry. While the settlement amount was substantial, it provides clarity and removes uncertainty, which could positively impact investor sentiment."},{"section":"3. Patent Litigation","text":"Teva faced patent infringement litigation from a competitor, potentially affecting their ability to market a key product. The outcome of this legal battle could have significant consequences for Teva's market position and revenue."},{"section":"4. Supply Chain Disruptions","text":"Teva encountered disruptions in its global supply chain due to unforeseen events, impacting the availability of certain drugs and manufacturing capabilities. This could lead to a decrease in sales and potential reputational damage if not resolved swiftly."},{"section":"5. Acquisition Plans","text":"Teva announced plans to acquire a smaller pharmaceutical company, aiming to expand its product portfolio and diversify revenue streams. Successful execution of this acquisition could enhance Teva's growth potential and long-term performance."},{"section":"6. Regulatory Changes","text":"Recent regulatory changes in key markets have impacted the pricing and reimbursement of pharmaceutical products. Teva's ability to adapt to these changes and navigate the evolving regulatory landscape will be critical for its future success."},{"section":"7. Market Competition","text":"Intensifying competition in the pharmaceutical industry, particularly in the generic drug segment, poses challenges for Teva. The company's ability to innovate and differentiate its products will play a crucial role in maintaining market share."},{"section":"8. COVID-19 Impact","text":"The ongoing COVID-19 pandemic has disrupted global healthcare systems and pharmaceutical supply chains. Teva's ability to manage the impact of the pandemic on its operations and distribution channels will be crucial for its financial performance."}],"tags":["CrossOver200","Long","Pharmaceuticals"],"news":[{"category":"company","date":1699194648,"headline":"Strong week for Teva Pharmaceutical Industries (NYSE:TEVA) shareholders doesn't alleviate pain of five-year loss","id":123648315,"image":"https://media.zenfs.com/en/simply_wall_st__316/86a1469f749f37c250391c4efaf3a309","symbol":"TEVA","publisher":"Yahoo","summary":"Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shareholders should be happy to see the share price up 11% in the...","url":"https://finance.yahoo.com/news/strong-week-teva-pharmaceutical-industries-143048488.html"},{"category":"company","date":1699182660,"headline":"Watching The Top 15 Israeli-Based Stocks Listed On Nasdaq - Some Improvement Over Last Week","id":123658878,"image":"","symbol":"TEVA","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3197209998"},{"category":"company","date":1699181400,"headline":"Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more","id":123658874,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3197197396"},{"category":"company","date":1698980700,"headline":"Teva Pharmaceutical Industries (TEVA) Shares Cross Above 200 DMA","id":123603609,"image":"","symbol":"TEVA","publisher":"Market News Video","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3194361607"},{"category":"company","date":1698938580,"headline":"Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated","id":123572447,"image":"https://media.zenfs.com/en/zacks.com/d29db872ee1db1747c2635048146aba8","symbol":"TEVA","publisher":"Yahoo","summary":"Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R\u0026D guidance.","url":"https://finance.yahoo.com/news/exelixis-exel-q3-earnings-sales-152300226.html"},{"category":"company","date":1698926400,"headline":"Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting","id":123569618,"image":"https://media.zenfs.com/en/business-wire.com/cc64c615d77ae34e4d77343a45ccd846","symbol":"TEVA","publisher":"Yahoo","summary":"TEL AVIV, Israel \u0026 PARSIPPANY, N.J., November 02, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new HD data will be presented at the Huntington Study Group® (HSG) Annual Meeting on November 2-4 in Phoenix, AZ.","url":"https://finance.yahoo.com/news/teva-present-data-supporting-safety-120000438.html"},{"category":"company","date":1698881460,"headline":"UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry","id":123564663,"image":"https://media.zenfs.com/en/business-wire.com/6ae1d496108f05eec8274e43a02c23bd","symbol":"TEVA","publisher":"Yahoo","summary":"TEL AVIV, Israel \u0026 PARSIPPANY, N.J., November 01, 2023--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release (RISE) study in The Lancet Psychiatry. The data supported the FDA approval for UZEDY, which was approved in April 2023 for the treatment of schizophrenia in adults as a subcutaneous injection every one or two months usin","url":"https://finance.yahoo.com/news/uzedy-risperidone-extended-release-injectable-233100997.html"},{"category":"company","date":1698821040,"headline":"Teva announces publication of efficiency/safety findings for UZEDY in The Lancet","id":123603615,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3190153641"},{"category":"company","date":1698698154,"headline":"13 Most Undervalued Pharma Stocks To Buy According To Analysts","id":123505333,"image":"","symbol":"TEVA","publisher":"Yahoo","summary":"In this piece, we will take a look at the 13 most undervalued pharmaceutical stocks to buy according to analysts. If you want to skip our overview of the pharma industry, then check out 5 Most Undervalued Pharma Stocks To Buy. The pharmaceutical industry is one of the biggest in the world and one that […]","url":"https://finance.yahoo.com/news/13-most-undervalued-pharma-stocks-203554710.html"},{"category":"company","date":1698690900,"headline":"Theravance Biopharma, Mylan Reach Settlement Over Inhalation Drug Yupelri","id":123512245,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"TEVA","publisher":"MarketWatch","summary":"By Sabela Ojea Theravance Biopharma, Mylan Ireland and Mylan Specialty have entered into a settlement agreement with Teva Pharmaceutical Industries over...","url":"https://www.marketwatch.com/story/theravance-biopharma-mylan-reach-settlement-over-inhalation-drug-yupelri-fab5470a"},{"category":"company","date":1698645180,"headline":"Theravance, Mylan settle patent litigation over COPD drug Yupelri","id":123511621,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185894890"},{"category":"company","date":1698640260,"headline":"Theravance Biopharma, Teva enter into settlement agreement related to Yupelri","id":123511622,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185747313"},{"category":"company","date":1698629100,"headline":"Teva call volume above normal and directionally bullish","id":123502226,"image":"","symbol":"TEVA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185442753"},{"category":"company","date":1698577500,"headline":"Pharma, PBMs spar over rising drug costs amid public scrutiny","id":123483527,"image":"","symbol":"TEVA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184120530"},{"category":"company","date":1698317640,"headline":"TEVA December 8th Options Begin Trading","id":123435645,"image":"","symbol":"TEVA","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179376908"},{"category":"company","date":1698238800,"headline":"Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program","id":123393743,"image":"https://media.zenfs.com/en/business-wire.com/b29e0f2135babc7599fc770773749eaf","symbol":"TEVA","publisher":"Yahoo","summary":"SANTA BARBARA, Calif. \u0026 PARSIPPANY, N.J., October 25, 2023--Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the continued funding of 11 local free and charitable clinics in the U.S. as part of a $2 million, two-year commitment, through their collaborative Community Routes: Access to Mental Health Care program that aims to advance access to health","url":"https://finance.yahoo.com/news/teva-second-round-funding-clinics-130000725.html"},{"category":"company","date":1698228780,"headline":"Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook","id":123395424,"image":"","symbol":"TEVA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3177250983"},{"category":"company","date":1698228300,"headline":"The Sound Shore Fund Q3 2023 Letter To Shareholders","id":123388735,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1002099850/image_1002099850.jpg?io=getty-c-w1536","symbol":"TEVA","publisher":"SeekingAlpha","summary":"The Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) declined 2.01% and 1.94%, respectively, in Q3 2023. Click here to read the full fund letter.","url":"https://seekingalpha.com/article/4643298-the-sound-shore-fund-q3-2023-letter-to-shareholders"},{"category":"company","date":1698213780,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Akebia Therapeutics (AKBA), Teva Pharmaceutical (TEVA) and Quest Diagnostics (DGX)","id":123392668,"image":"","symbol":"TEVA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3176929242"}]}